Clinical Trial Update: N-Acetyl Cystein and Contrast Nephropathy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating N-acetylcysteine for prevention of radiographic contrast–induced nephropathy in patients with chronic kidney disease, status c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Contrast-induced Nephropathy

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Imam Khomeini Hospital | Conditions: Chronic Kidney Disease Stage 2, Radiographic Contrast Agent Nephropathy | Phase 3 | Status: UNKNOWN